{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:29:56Z","timestamp":1780774196062,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","award":["UL1TR001442"],"award-info":[{"award-number":["UL1TR001442"]}],"id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001442"],"award-info":[{"award-number":["UL1TR001442"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2P30CA023100-33"],"award-info":[{"award-number":["2P30CA023100-33"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["FA1-00607"],"award-info":[{"award-number":["FA1-00607"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["STAR Protocols"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.xpro.2021.100565","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T05:23:03Z","timestamp":1622092983000},"page":"100565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells"],"prefix":"10.1016","volume":"2","author":[{"given":"Ashni A.","family":"Vora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-1701","authenticated-orcid":false,"given":"Phoebe K.","family":"Mondala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3405-5937","authenticated-orcid":false,"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Robert","family":"MacLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Crews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xpro.2021.100565_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2018.07.025","article-title":"IRF4 in multiple myeloma-Biology, disease and therapeutic target","volume":"72","author":"Agnarelli","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.xpro.2021.100565_bib2","doi-asserted-by":"crossref","first-page":"85392","DOI":"10.18632\/oncotarget.19907","article-title":"Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xpro.2021.100565_bib3","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/eji.201970107","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)","volume":"49","author":"Cossarizza","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xpro.2021.100565_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/2040620716677523","article-title":"An update on the role of daratumumab in the treatment of multiple myeloma","volume":"8","author":"Costello","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.xpro.2021.100565_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/fon-2017-0493","article-title":"Therapy sequencing strategies in multiple myeloma: who, what and why?","volume":"14","author":"Costello","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.xpro.2021.100565_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.stem.2016.08.003","article-title":"RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML","volume":"19","author":"Crews","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xpro.2021.100565_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12967-014-0370-3","article-title":"An RNA editing fingerprint of cancer stem cell reprogramming","volume":"13","author":"Crews","year":"2015","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.xpro.2021.100565_bib8","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust isolation of malignant plasma cells in multiple myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xpro.2021.100565_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.leu.2404895","article-title":"Expression of MUM1\/IRF4 mRNA as a prognostic marker in patients with multiple myeloma","volume":"22","author":"Heintel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.xpro.2021.100565_bib10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1073\/pnas.1213021110","article-title":"ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.xpro.2021.100565_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrc.2017.23","article-title":"RNA editing-dependent epitranscriptome diversity in cancer stem cells","volume":"17","author":"Jiang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xpro.2021.100565_bib12","doi-asserted-by":"crossref","first-page":"108670","DOI":"10.1016\/j.celrep.2020.108670","article-title":"Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution","volume":"34","author":"Jiang","year":"2021","journal-title":"Cell Reports"},{"key":"10.1016\/j.xpro.2021.100565_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xpro.2021.100565_bib14","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41467-017-01890-w","article-title":"Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma","volume":"8","author":"Lazzari","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xpro.2021.100565_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF01697400","article-title":"Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells","volume":"64","author":"Leo","year":"1992","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.xpro.2021.100565_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xpro.2021.100565_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.stem.2020.12.017","article-title":"Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption","volume":"28","author":"Mondala","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xpro.2021.100565_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cyto.b.21279","article-title":"Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents","volume":"90","author":"Muccio","year":"2016","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.xpro.2021.100565_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.xpro.2021.100565_bib20","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.xpro.2021.100565_bib21","doi-asserted-by":"crossref","first-page":"100248","DOI":"10.1016\/j.xpro.2020.100248","article-title":"Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting","volume":"2","author":"Stevens","year":"2021","journal-title":"STAR Protoc."}],"container-title":["STAR Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666166721002720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666166721002720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:52:05Z","timestamp":1778917925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666166721002720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2666166721002720"],"URL":"https:\/\/doi.org\/10.1016\/j.xpro.2021.100565","relation":{},"ISSN":["2666-1667"],"issn-type":[{"value":"2666-1667","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells","name":"articletitle","label":"Article Title"},{"value":"STAR Protocols","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xpro.2021.100565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.stem.2020.12.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"100565"}}